News | March 25, 2026
ImmunityBio scores first Asian approval for ANKTIVA in Macau
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The endorsement follows overwhelming support for the share swap preceding the merger,
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
Subscribe To Our Newsletter & Stay Updated
